Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells 96,517 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. The trade was a 16.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Fractyl Health Price Performance

Shares of GUTS stock opened at $1.97 on Friday. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50. The stock has a market capitalization of $94.52 million and a price-to-earnings ratio of -0.16. The stock has a fifty day simple moving average of $2.58 and a two-hundred day simple moving average of $4.03. The company has a current ratio of 5.58, a quick ratio of 7.46 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. On average, analysts predict that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Fractyl Health during the 3rd quarter valued at about $25,000. Rhumbline Advisers acquired a new position in Fractyl Health during the 2nd quarter valued at about $32,000. SG Americas Securities LLC acquired a new position in Fractyl Health during the 3rd quarter valued at about $33,000. HighTower Advisors LLC acquired a new position in Fractyl Health during the 3rd quarter valued at about $38,000. Finally, Beta Wealth Group Inc. acquired a new position in Fractyl Health during the 3rd quarter valued at about $44,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.